Table 1.

Efficacy of IRE on PDAC.

Author	Number of patients	Approach	Type of study	Survival (mo.)
Martin et al. [23]	54	Open (52) Percutaneously (2)	Propensity-matched comparison with standard chemo- or chemoradiation	20.2
Martin et al. [24]	200	Open	Data from multicenter registry	24.9
Trueba-Arguiñarena et al. [25]	1	Percutaneously	Case report	f-up 12 mo.
Narayanan et al. [26]	43	Percutaneously	Prospective	16.2
Belfiore et al. [27]	20	Percutaneously	Retrospective	12.9
Pai et al. [28]	5	Percutaneously	Phase-1 safety and feasibility	Range 1–6 mo.
Paiella et al. [29]	10	Open	Phase-1 safety and feasibility	Median 6.4, range 2.9–15.9